Roel van Kampen
Overview
Explore the profile of Roel van Kampen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smits F, Smits F, Groen K, Levin M, Stege C, Stege C, et al.
Blood
. 2024 Nov;
145(5):543-546.
PMID: 39576961
The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic frailty assessment improved the prediction of survival and early mortality...
2.
van Bruggen J, Peters F, Mes M, Rietveld J, Cerretani E, Cretenet G, et al.
Blood Adv
. 2024 Jul;
8(17):4633-4646.
PMID: 39042920
Autologous T-cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy, exhibit low success rates in chronic lymphocytic leukemia (CLL) and correlate with a dysfunctional T-cell phenotype observed in patients....
3.
Visentin A, Chatzikonstantinou T, Scarfo L, Kapetanakis A, Demosthenous C, Karakatsoulis G, et al.
Am J Hematol
. 2023 Sep;
98(12):1856-1868.
PMID: 37772428
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B...
4.
Rodrigues D, van Kampen R, van Bodegraven A, Kleinjans J, Jennen D, de Kok T
Toxicol Lett
. 2022 Oct;
371:17-24.
PMID: 36183961
Capecitabine is a chemotherapeutic drug that is widely used as a monotherapy option in advanced cancer patients. After administration, it is converted into its active metabolite 5-fluorouracil (5-FU), a cytotoxic...
5.
Chatzikonstantinou T, Kapetanakis A, Scarfo L, Karakatsoulis G, Allsup D, Cabrero A, et al.
Leukemia
. 2021 Nov;
35(12):3444-3454.
PMID: 34725454
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome...
6.
Haselager M, Thijssen R, West C, Young L, van Kampen R, Willmore E, et al.
Cell Death Differ
. 2021 Jan;
28(5):1658-1668.
PMID: 33495554
In chronic lymphocytic leukemia (CLL), the lymph node (LN) microenvironment delivers critical survival signals by inducing the expression of anti-apoptotic Bcl-2 members Bcl-XL, Bfl-1, and Mcl-1, resulting in apoptosis blockade....
7.
Martens A, Janssen S, Derks I, Adams Iii H, Izhak L, van Kampen R, et al.
J Immunother Cancer
. 2020 Jun;
8(1).
PMID: 32581054
Background: Bispecific antibodies are promising new therapeutics in B cell malignancies. Whether they lead to potent T cell activation despite described T cell dysfunction in chronic lymphocytic leukemia (CLL), and...
8.
Abbema D, van Vuuren A, van den Berkmortel F, van den Akker M, Deckx L, Buntinx F, et al.
J Geriatr Oncol
. 2017 Feb;
8(3):176-184.
PMID: 28159513
Objectives: The aim of the present study was to disentangle the impact of age and that of cancer diagnosis and treatment on functional status (FS) decline in older patients with...
9.
Lobbezoo D, Truin W, Voogd A, Roumen R, Vreugdenhil G, Dercksen M, et al.
Oncotarget
. 2016 Apr;
7(20):29412-9.
PMID: 27121067
Introduction: This study describes the differences between the two largest histological breast cancer subtypes (invasive ductal carcinoma (IDC) and invasive (mixed) lobular carcinoma (ILC) with respect to patient and tumor...